Details for Patent: 8,486,975
✉ Email this page to a colleague
Which drugs does patent 8,486,975 protect, and when does it expire?
Patent 8,486,975 protects DELSTRIGO and PIFELTRO and is included in two NDAs.
This patent has seventy-three patent family members in forty-four countries.
Summary for Patent: 8,486,975
| Title: | Non-nucleoside reverse transcriptase inhibitors |
| Abstract: | Heteroaromatic compounds of Formula I: ##STR00001## are HIV reverse transcriptase inhibitors, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. |
| Inventor(s): | Burch; Jason (Redwood City, CA), Cote; Bernard (Notre-Dame-de-I'lle-Perrot, CA) |
| Assignee: | Merck Canada Inc. (Kirkland, Quebec, CA) |
| Application Number: | 13/073,631 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,486,975
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO | ⤷ Sign Up | ||
| Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY | ⤷ Sign Up | ||
| Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,486,975
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2552902 | ⤷ Sign Up | 300980 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2552902 | ⤷ Sign Up | PA2019506 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2552902 | ⤷ Sign Up | LUC00113 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
